Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 13 results found. Search for [ current good manufacturing practice (CGMP) regulations ]

Results 1 to 13 of 13
PB Jayakumar
New Delhi, November 7, 2019
Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year


PB Jayakumar
November 6, 2019
Most violations relate to rectifiable documentation, data maintenance, batch-wise consistent production quality, data on supply chain, stability issues, microbial contamination and quality checks


Reuters
July 17, 2019
The U.S. Food and Drug Administration (FDA) said it found adulteration and \"significant violations\" of current good manufacturing practice (CGMP) regulations at Strides Pharma Sciences Ltd's plant in Puducherry in south India.


PTI
April 28, 2019



PTI
April 21, 2019



PTI
March 31, 2019



BusinessToday.In
January 28, 2019
The large cap stock fell up to 4.70%  to 746.70 level compared to the previous close of 783.40 on the BSE.  It closed 3% or 23.50 points lower at 759.90 level on BSE.


PTI
January 27, 2019



PTI
New Delhi, August 19, 2015
The US regulator said its inspectors found significant violations in the three manufacturing facilities in Bengaluru, which is an arm of US-based Mylan Inc. Of the three units, two plants belonged to Agila Specialties, which Mylan had acquired from Strides Arcolab in 2013-end. The other unit is owned by Mylan Laboratories.


E Kumar Sharma
December 24, 2014
Sun Pharmaceutical's move to acquire Ranbaxy is arguably the high point of 2014 for the pharmaceutical sector.


E. Kumar Sharma
February 26, 2014
The US regulators increased scrutiny of Indian drug exporters is giving the pharmaceutical industry the jitters. Besides becoming more frequent, inspections are also more often unannounced. Adding to Indian drug makers anxiety is the nature and scope of the inspections.


PTI
August 6, 2013
 Ranbaxy facilities in India are being reviewed after its US arm admitted to manufacturing certain drugs not in conformity with good manufacturing practices and which are considered \"adulterated\" under US law, Health Minister Gulam Nabi Azad said on Tuesday.


E Kumar Sharma
July 26, 2013
Drug Controller General of India (DCGI) G. N. Singh also said medicines sold in India are safe, ruling out any reason for panic.


PAGES 1 OF 1